Figure 5.

Everolimus enhances [pemetrexed + fingolimod] lethality. A. NSCLC cells were treated with vehicle control, [pemetrexed (500 nM) + fingolimod (200 nM)], everolimus (50 nM) or the three drugs in combination for 12h. Cells were then isolated and viability determined via a live/dead assay (n = 3 ± SEM). # p < 0.05 greater value than [pemetrexed + fingolimod] treatment alone. B. Wild type parental H1975 clones and afatinib-resistant H1975 clones were treated with vehicle control, [pemetrexed (500 nM) + fingolimod (200 nM)], everolimus (50 nM) or the three drugs in combination for 12h. Cells were then isolated and viability determined via a live/dead assay (n = 3 ± SEM). * p < 0.05 less than 100%.